

**Gale Group New Product Announcements/Plus®** contains the full text of press releases from all industries covering announcements related to products, with a focus on new products and services. In addition to product descriptions, press releases generally contain key details about new products and technologies, including technical specifications, availability, uses, licensing agreements, distribution channels, and prices. Contacts and phone numbers are often provided to allow follow-up by interested parties. The press releases contained in the NPA/PLUS database are obtained directly from the product manufacturer, distributor, or an authorized marketing representative.

The **NPA/PLUS** database provides information on the introduction of new products and services in all areas, including:

- Agriculture, Forestry, Fisheries
- Apparel and Related Products
- Chemicals and Allied Products
- Communications
- Electric/Electronic Machinery Equipment
- Financial Services
- Food and Kindred Products
- Furniture
- Instruments and Related Products
- Leather and Products
- Medical and Health Services
- Metals and Fabricated Metal Products
- Mining and Extractive Industries
- Ordnance
- Other Kinds of Manufacturing
- Paper and Allied Products
- Petroleum and Energy Products
- Printing and Publishing
- Rubber and Allied Products
- Sciences
- Service Industries
- Stone, Clay, and Glass Products
- Textile Mill Products
- Tobacco Products
- Transportation
- Transport Equipment
- Wood and Wood Products

**Date Coverage**

1985–2013

**Update Frequency**

Closed

**Geographic Coverage**

International

**Document Types**

News wires

**Publisher**

Gale Group New Product Announcements/Plus® is provided by Gale, a part of Cengage Learning.

Gale, a part of Cengage Learning  
 27500 Drake Road  
 Farmington Hills, MI 48331-3535  
 USA

# Gale Group New Product Announcements / Plus®

Full text [← Back to results](#)

Add to selected items [Save to My Research](#) [Email](#)

TI  
PUB,PD,YR

## PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

**PR Newswire** 15 Jan 2014: NA.

TX

Full Text [Translate](#)

NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

[http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm\\_source=prnewswire&utm\\_medium=pr&utm\\_campaign=Pathology](http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)

PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022

### Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData's July 2013 survey suggests a highly crowded, genericized market.

### Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.

### Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more

informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 112.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 143.2 Symptoms 184 Disease Management 204.1 Diagnosis 204.2 Treatment Overview 224.3 India 284.3.1 Diagnosis 284.3.2 Clinical Practice 305 Competitive Assessment 315.1 Overview 315.2 Strategic Competitor Assessment 325.3 Product Profiles - Major Brands 335.3.1 Protopic (tacrolimus) 335.3.2 Elidel 405.3.3 Cyclosporine (numerous generic names) 465.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 496 Opportunity and Unmet Need 516.1 Overview 516.2 Unmet Needs 526.2.1 A Systemic Drug for Severe Recalcitrant Patients 526.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 546.2.3 A Drug that Effectively Controls Patients' Pruritus 556.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 566.2.5 A Drug that Induces Disease Remission 576.2.6 Improved Quality of Life for Both Patients and their Carers 586.3 Unmet Needs Gap Analysis 586.4 Opportunities 606.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 606.4.2 Predictive Tests for Patient Stratification 606.4.3 More Therapeutic Options that Address Patients' Pruritus 617 Pipeline Assessment 627.1 Overview 627.2 Promising Drugs in Clinical Development 647.2.1 Phase II Pipeline Products 668 Market Outlook 678.1 Global Drivers and Barriers 678.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease 678.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity 688.1.3 Driver: A drug that is able to

(. . .)

#### 1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 19Table 2: Treatment Guidelines for Atopic Dermatitis 25Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27Table 4: Referral Rates to an Indian Dermatologist, Split by Severity and Specialist Type, 2013 28Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in India in 2012 29Table 6: Leading Treatments for Atopic Dermatitis, 2013 33Table 7: Product Profile - Protopic 35Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 36Table 9: Protopic SWOT Analysis, 2013 39Table 10: Product Profile - Elidel 41Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 42Table 12: Elidel SWOT Analysis, 2013 45Table 13: Product Profile - Cyclosporine 47Table 14: Cyclosporine SWOT Analysis, 2013 49Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 50Table 16: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 52Table 17: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 59Table 18: Late-Stage Atopic Dermatitis Pipeline, 2013 64Table 19: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 65Table 20: Phase II and Phase I Atopic Dermatitis Pipeline, 2013 66Table 21: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 67Table 22: Sales Forecasts (\$m) for Atopic Dermatitis in India, 2012-2022 74Table 23: Key Event Impacting Sales for Atopic Dermatitis in India, 2012-2022 75Table 24: Atopic Dermatitis Market in India - Drivers and Barriers, 2012-2022 76Table 25: Physicians Surveyed, By Country 91

#### 1.2 List of Figures

Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 16Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 23Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022 64Figure 4: Sales for Atopic Dermatitis in India by Drug Class, 2012-2022 75



To order this report: PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 [http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm\\_source=prnewswire&utm\\_medium=pr&utm\\_campaign=Pathology](http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)

Contact Clare: [clare@reportlinker.com](mailto:clare@reportlinker.com) US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

WC

Word count: **1193**  
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 **Indexing (details)**  [Cite](#)

BDE,SU

**Business subject** [Atopic dermatitis -- Reports;](#)  
[Forecasts and trends;](#)  
[Market trend/market analysis;](#)  
[Pharmaceutical industry -- Forecasts and trends;](#)  
[Pharmaceutical industry -- Reports;](#)  
[Reports](#)

LOC,SU	Location	France
CO,ORG, SU	Company / organization	Sanofi S.A.; Sanofi S.A. (Forecasts and trends); Sanofi S.A. (Reports)
IF,SU	Identifier (keyword)	Trade, Elidel (Medication) (Reports), Protopic (Medication) (Reports)
EVT,CC	Event classification	010: Forecasts, trends, outlooks
NAICS,CC	NAICS classification	325411: Medicinal and Botanical Manufacturing
PRCC,CC	Product classification	2834000: Pharmaceutical Preparations
SIC,CC	SIC classification	2833: Medicinals and botanicals; 2834: Pharmaceutical preparations
TI	Title	PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
OTI	Alternate title	PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
PUB	Publication title	PR Newswire
PG	Pagination	NA
PD,YR	Publication date	Jan 15, 2014
PUB	Publisher	PR Newswire Association LLC
JSU	Journal subject	Business, News, opinion and commentary
JC	Journal code	4PRN
PSTYPE	Source type	Newswire
LA	Language of publication	English
DTYPE	Document type	Magazine/Journal
AN	Source attribution	Gale Group New Product Announcements Plus, © Publisher specific
	Accession number	355635342
	Document URL	<a href="http://search.proquest.com/professional/docview/1477907413?accountid=137296">http://search.proquest.com/professional/docview/1477907413?accountid=137296</a>
	Copyright	Copyright 2014 Gale, Cengage Learning. All rights reserved. COPYRIGHT 2014 PR Newswire Association LLC
DCRE	Date created	2014-01-16
UD	Updates	2014-01-17
FAV	First available	2014-01-17
	Database	Gale Group New Product Announcements / Plus® (1985 - current)

## Search Fields

Field Name	Field Code	Example	Description and Notes
Accession number	AN	an(355635342)	A unique document identification number assigned by Gale.
All fields (no full text)	ALL	all(systemic vitamin derivatives)	The search includes all fields <i>except</i> Document text (TX).
All fields + text	--	systemic vitamin derivatives	Includes all fields including the document text.
Author Author First Name Author Last Name	AU AUFN AULN	au(binstock, andrew) aufn(andrew) auln(binstock)	Includes all Authors.
First author	FAU	fau(poor alfred)	First name listed in Author field. Punctuation is not required.
Business subject	BDE	bde("forecasts and trends")	
Classification	CC	cc(forecasts, trends, outlook) cc(010)	Field code CC searches both the codes and the terms for SIC, NAICS, Event & Product classifications.
Advertising classification	ADC	adc(34: Research Findings)	Also searchable with field code CC.

Field Name	Field Code	Example	Description and Notes
Event classifications <sup>1</sup>	EVT	evt(010: forecasts, trends, outlooks)	Also searchable with field code CC.
NAICS <sup>1</sup>	NAICS	naics(325411: medicinal and botanical manufacturing) naics(325411)	Also searchable with field code CC.
Product classification <sup>1</sup>	PRCC	prcc(2834000: pharmaceutical preparations)	Also searchable with field code CC.
US SIC	SIC	sic(2833) sic(medicinals and botanicals) sic(2833: medicinals and botanicals)	Also searchable with field code CC.
Company/organization <sup>1</sup>	CO, COM	co(sanofi s.a.)	Also searchable with field code ORG.
Date created	DCRE	dcre(2014-01-16)	The date on which the information provider created the record. Date range searching is supported.
Dateline	DLN	dln(mumbai)	
Document ID			See Accession number.
Document text	TX	tx("systemic vitamin derivatives")	
Document title	TI	ti("PharmaPoint: Atopic Dermatitis - India Drug Forecast")	Includes alternate title (OTI) and subtitle, but not Publication Title (PUB).
Alternate title	OTI	oti("meningococcal vaccine*")	Includes title, alternate title, subtitle and original language of document title, if available. Field code TI also searches the Alternate title.
Title only	TIO	tio(meningococcal vaccine*)	Searches only the Title, not alternate title or subtitle.
Document type	DTYPE	dtype(magazine/journal)	
First available	FAV	fav(2014-01-17)	Indicates the first time a document was loaded in a specific database on Dialog. It will not change regardless of how many times the record is subsequently reloaded, as long as the accession number does not change.
From database <sup>2</sup>	FDB	co(innovex inc.) AND fdb(galenevproduct) co(innovex inc.) AND fdb(1008441)	Useful in multi-file searches to isolate records from a single file.
Full text present	FTANY	("topical calcineurin inhibitors") AND ftany(yes)	Add: <i>AND FTANY(YES)</i> to a query to limit your search to articles with full text.

<sup>1</sup> A Lookup/Browse feature is available for this field in the Advanced Search dropdown or in Browse fields.

<sup>2</sup> Go to Field Codes Help in Advanced Search. Click 'Search' from the bottom left nav. Enter: "fdb" and click: Search. Then click: "Targeting databases when you search," which will retrieve the list of database names and codes that can be searched with FDB.  
Page 5

Field Name	Field Code	Example	Description and Notes
Identifier (Keyword)	IF	if(trade)	
ISSN	ISSN	issn(1541-0595) issn(15410595)	
Issue	ISS	iss(6)	
Journal code	JC	jc(4PRN)	Assigned by the information provider identifying a specific source.
Language	LA	la(english) la(eng)	
Lead paragraph	LP	lp("american heart association")	Displayed in the Preview pane
Location	LOC, LO	loc(france)	
Pagination	PG	pg(1)	
Person <sup>1</sup>	PER	per(amoury)	
Publication date	PD	pd(20140115) pd(>201205)	Date range searching is supported.
Publication title <sup>1</sup>	PUB	pub.exact("pr newswire")	The database is sourced from two publications: PR Newswire and Business Wire only. A handful of records can be found from other publications,
Publication year	YR	yr(2010) yr(2012-2013) yr(>2011)	Date range operators are supported.
Publisher	PB	pb("pr newswire association llc")	
Source type	PSTYPE	pstype(newswire)	PSTYPE searches IP-supplied values; STYPE searches Dialog-normalized values.
Subject	SU	su(medical equipment industry)	SU field code search includes Gale subject indexing, target audience, journal subject, SIC and NAICS terms, location/geo terms. Subject Look up is more limited.
Ticker symbol	TKS	tk(sny)	
Updated	UD	ud(2014-01-17)	The date(s) the record was loaded as a result of an update provided by the supplier.
Volume	VO	vo(11)	
Word count	WC	wc(1193) wc(>=1000)	

## Search Tools

Field codes are used to search document fields, as shown in the sample document. Field codes may be used in searches entered on the **Basic Search**, **Advanced Search**, and **Command Line** search pages. **Limit options**, **Look up lists**, and **"Narrow results by" filters** tools are available for searching. Some data can be searched using more than one tool.

## Limit Options

Limit options are quick and easy ways of searching certain common concepts. Check boxes are available for:

### Full text

Short lists of choices are available for:

## Source type, Document type, Language

**Date limiters** are available in which you can select single dates or ranges **Publication date** and **Updated**.

## Lookup Lists

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced Search form. Look Up lists are available in the fields drop-down for:

### Companies/organizations, People, Locations

and additionally in the fields drop-down for:

### Publications, Event classifications, NAICS, Product classifications

## “Narrow Results by” Filters

When results of a search are presented, the results display is accompanied by a list of “Narrow results by” options shown on the right-hand panel. Click on any of these options and you will see a ranked list showing the most frequently occurring terms in your results. Click on the term to apply it to (“narrow”) your search results. “Narrow results by” filters include:

**Full text, Source type, Publication title, Document type, Author, Subject, NAICS classification, Product classification, SIC classification, Company/organization, Location, Person, Language, Publication date**

## Look Up Citation

If you need to trace a particular bibliographic reference, use the Look Up Citation feature. Find a link to this toward the top left of the Advanced Search page, or in the drop list under Advanced on any search form; click this and you will go to a form where you can enter any known details of the citation, including:

**Document title, Author, Publication title, ISSN, ISBN, Volume, Issue, Page, Date, DOI**

## Document Formats

Document Format	Fields	Online	Export / Download
<b>Brief view</b>	Title and Publication date	✓	
<b>Detailed view</b>	Same as Brief view plus a 3-line KWIC window	✓	
<b>KWIC (Keyword in Context)</b>	Detailed view plus all occurrences of your search terms, highlighted within the fields where the terms occur	✓	✓
<b>Preview</b>	Title, Author, Publication title, Publisher, Volume, Issue, Pagination, Publication date, Abstract, Subject	✓	
<b>Brief citation</b>	Bibliographic record minus Indexing	✓	✓

<b>Full text</b>	Complete record with full text	✓ <sup>3</sup>	✓
<b>Custom</b>	Choose the fields you want.		✓ <sup>4</sup>

## Terms & Conditions

TERMS AND CONDITIONS: For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply. These Databases (the "Databases") are copyrighted by Gale, a part of Cengage Learning. The Gale Databases are provided "as is" without warranty of any kind. Neither Gale, a part of Cengage Learning, nor any of its data suppliers make any warranty whatsoever as to the accuracy or completeness of any of the Databases or the results to be obtained from using the information contained therein and neither Gale, a part of Cengage Learning, nor any of its data suppliers shall be responsible for any claims attributable to errors, omissions or other inaccuracies in the information contained in any Gale Databases. The entire risk as to the results and performance of any Gale Database is assumed by the user of that Database. Further, neither Gale, a part of Cengage Learning, nor any of its data suppliers make any representations or warranties either express or implied, with respect to any of the Databases, including, but not limited to, the quality, performance, merchantability or fitness for a particular purpose of any Gale Database or any information contained therein. In no event shall Gale, a part of Cengage Learning, or any of its data suppliers be liable for direct, indirect, special, incidental or consequential damages arising out of the use of or inability to use any Gale Database or for any loss or damage of any nature caused to any person as a result of the use of the Database. Material contained in any Database may not be sold. Material contained in any Database may not be made available in any manner whatsoever to a third party or duplicated, redistributed or archived except solely for the customer's own internal use and according only to (1) the Terms & Conditions in Dialog's Standard Service Agreement and (2) the terms and conditions contained below. A user may not: - redistribute, copy or electronically store (archive) all or a majority of records from a single issue of a publication retrieved from the Databases. - electronically store (archive) in machine-readable form for more than twelve (12) months records or data retrieved from the Databases under the DIALOG archival feature. - delete or remove from a record or data the copyright credits or the name of the Database from which such record or data was retrieved. - republish, distribute or make available in any manner whatsoever to third parties who are not part of the user's organization records or data retrieved from the Databases. - use any records or data to create a derivative work except for a compilation of electronically stored data for internal use only. - electronically store in machine-readable form for longer than fifteen (15) days records or data retrieved for internal redistribution under the DIALOG redistribution feature (non-archival storage use). - redistribute, copy or electronically store (REDIST, COPIES or ARCHIVE commands) materials retrieved from the Newsletter Database™, or from the following journals: Journal of the American Medical Association Archives of Internal Medicine American Medical News - redistribute, copy or electronically store (REDIST, COPIES or ARCHIVE commands) more than 500 copies of a record without permission from Dialog's and Gale, a part of Cengage Learning. Notwithstanding the above restrictions, a bona fide information broker may make and provide one copy of search results obtained from the Databases to a single customer outside that information broker's organization provided that such information broker notifies such single customer that the information is copyrighted material which can be used for internal purposes only and cannot be copied, sold or republished. IF THERE IS A CONFLICT BETWEEN THESE TERMS AND CONDITIONS AND Dialog's CUSTOMER SUBSCRIPTION AGREEMENT, INCLUDING ANY ADDITIONAL TERMS ON REDISTRIBUTION AND ARCHIVE USES, THE ABOVE TERMS AND CONDITIONS SHALL GOVERN. ANY OTHER USE OF THE DATABASES WITHOUT EXPRESS WRITTEN PERMISSION IS STRICTLY PROHIBITED.

<sup>3</sup> In Online-view mode, Dialog gives access to two Document Formats only: *Brief citation*, and the 'most complete' format available. Depending on the database, or the amount of data available for a record, the most complete format may be any one of *Citation*, *Citation/Abstract*, *Full text*, or *Full text – PDF*.

<sup>4</sup> Custom export/download format is available in the following mediums only: HTML, PDF, RefWorks, RTF, Text only, XLS.



[Dialog Standard Terms & Conditions](#) apply.

Contact: **Dialog Global Customer Support**  
Email: [Customer@dialog.com](mailto:Customer@dialog.com)  
Within North America **1 800 334 2564**  
Outside North America **00 800 33 34 2564**